Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 21 (2), 115-21

New Perspectives on the Management of Hepatocellular Carcinoma With Portal Vein Thrombosis


New Perspectives on the Management of Hepatocellular Carcinoma With Portal Vein Thrombosis

Hyun Young Woo et al. Clin Mol Hepatol.


Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging. PVT is present in 10-40% of HCC cases at the time of diagnosis and its therapeutic options are very limited. Current guidelines mainly recommend sorafenib for advanced HCC with PVT, but surgery, transarterial chemoemolization, external radiation therapy, radioembolization, transarterial infusion chemotherapy, and combination therapy are also still used. Furthermore, several new emerging therapies such as the administration of immunotherapeutic agents and oncolytic viruses are under investigation. This comprehensive literature review presents current and future management options with their relative advantages and disadvantages and summary data on overall survival.

Keywords: Hepatocellular carcinoma; Management; Portal vein thrombosis.

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts to disclose.

Similar articles

See all similar articles

Cited by 12 PubMed Central articles

See all "Cited by" articles


    1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255. - PubMed
    1. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7:448–458. - PMC - PubMed
    1. Cheung TK, Lai CL, Wong BCY, Fung J, Yuen MF. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther. 2006;24:573–583. - PubMed
    1. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MDC, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62–67. - PubMed
    1. Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut. 2001;48:103–109. - PMC - PubMed

Publication types

MeSH terms